PTC Therapeutics, Inc.
PTCT US
PTCT USPTC Therapeutics, Inc.
United States Composite- Business
- PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Company News
PTC Therapeutics First Quarter 2024 Earnings: Beats Expectations
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Q1 2024 PTC Therapeutics Inc Earnings Call
PTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
PTC Therapeutics Q1 2024 Earnings: A Detailed Financial Review
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
A Comprehensive Look at Sarepta's Growth and Innovation
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
PTC Therapeutics Provides Key Regulatory Updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Released Its Yearly Earnings: Here's What Analysts Think